Plus Therapeutics Announces Webinar to Present ReSPECT Glioblastoma Clinical Trial Update (GlobeNewswire) - Nov 13, 2020 - "Plus Therapeutics, Inc...announced it will host a webinar on Thursday, November 19, 2020, 4:30 to 5:30 p.m. ET. The call will follow a poster presentation of new interim data from the ongoing National Institutes of Health-sponsored ReSPECT™ Phase 1 clinical trial evaluating the Company's lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM) at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting.....The sixth and final dose escalation cohort of the ReSPECT trial is underway and is expected to fully enroll by the end of 2020."
P1 data • Trial status • Glioblastoma • Oncology
|